Skip to content
Open access

Parsing the relationships among gut microbiome, neurotransmitter metabolome, glymphatic function, and cognition across healthy elderly, mild cognitive impairment, and probable Alzheimer's disease.

Oct 2026 · Brain, behavior, and immunity · Vol 139, pp. 107067 · 0 citations · 78 references
Medicine

TL;DR

The gut microbiome, neurotransmitter metabolome, and a variety of glymphatic markers were measured in patients with clinically diagnosed probable AD and showed a wide range of associations, which may inform future preventive and therapeutic interventions by targeting the established pathways.

Abstract

Background

Evidence has suggested brain glymphatic dysfunction and gut microbial metabolic disturbance in Alzheimer's disease (AD), yet the relationships among gut microbiota, neurotransmitter metabolites, glymphatic function, and cognition across clinically defined groups of healthy elderly, mild cognitive impairment (MCI), and probable AD remain unclear.

Methods

Using metagenomic sequencing, targeted metabolomics, and multi-modal magnetic resonance imaging, we measured the gut microbiome, neurotransmitter metabolome, and a variety of glymphatic markers in 30 patients with clinically diagnosed probable AD, 75 individuals with MCI, and 59 healthy controls (HC).

Results

Although global microbial diversity showed no group difference, MCI and AD showed shared and unique species-level microbial alterations relative to HC. Despite the absence of overall metabolomic divergence, AD exhibited reduced levels of multiple neurotransmitter metabolites compared with MCI and HC. Prominent alterations in multiple glymphatic markers were present in AD rather than in MCI. Further integrated analyses revealed a wide range of associations among these multi-omics changes and established potential serial mediation pathways, manifesting as a pattern of gut microbiota → neurotransmitter metabolites → glymphatic function → cognition.

Conclusions

These findings could enrich our understanding of the biological mechanisms involved in cognitive impairment and clinically diagnosed probable AD, but also may inform future preventive and therapeutic interventions by targeting the established pathways.

Read PDF

Similar papers

Open access Oct 2026

Integrated gut microbiome and fecal metabolome profiling identifies taurine-associated microbial dysbiosis across the Alzheimer’s disease clinical spectrum

Integrated multi-omic profiling reveals coordinated microbiome–metabolome dysregulation across the AD clinical spectrum, with taurine as a candidate microbial–metabolic node linking gut dysbiosis to cognitive performance.

Yi Feng, Yao Sha, Lu-Lu Xu et al. · 0 citations
Open access Nov 2026

Four-axis fecal metabolome alterations and an exploratory 5-metabolite signature for detecting subjective cognitive decline across the clinically defined Alzheimer's disease spectrum

The gut-brain axis is implicated in Alzheimer's disease (AD), but fecal metabolomic changes across the healthy controls (HC)→subjective cognitive decline (SCD)→mild cognitive impairment (MCI)→AD clinical spectrum, especially at the SCD stage, remain poorly characterized. Without amyloid/tau confirmation, our groups...

Yi Feng, Rong-Qin Wu, Yu-Ming Chen et al. · 0 citations
Open access Oct 2026

Profiling Gut Microbiome and Metabolites Aids Diagnosis and Prediction of Progression in Mild Cognitive Impairment

Accumulating evidence suggests a link between the gut microbiota and metabolome and mild cognitive impairment (MCI); however, it remains largely unknown whether these parameters can aid MCI diagnosis and predict disease progression. We comprehensively characterized gut microbiota and metabolomic profiles in fecal sampl...

Bi-Rong Zhang, Richard Brown, A. Bayer et al. · 0 citations
Review Open access Sep 2026

Microbiota-derived metabolite signatures in Alzheimer’s disease across the cognitive aging continuum: a human-focused systematic review and evidence-weighted knowledge graph

Background Gut microbial metabolism is increasingly implicated in Alzheimer’s disease (AD), mild cognitive impairment (MCI), preclinical amyloid accumulation, and cognitive aging. However, existing reviews often focus on microbial taxonomy rather than the metabolite mediators that connect the gut ecosystem with AD path...

Xiao-Teng He, Li-Li Zhang, Cai-Qiu Song et al. · 0 citations
Review Open access Oct 2026

Microbiome-targeted strategies for Alzheimer’s disease: multi-omics signatures, mechanistic links, and intervention evidence

Alzheimer’s disease (AD) is increasingly studied in relation to gut microbial mechanisms because microbial metabolism, mucosal barrier function, and peripheral immune activation may influence neuroinflammation and host metabolic stress. This review evaluates microbiome-linked evidence in AD with emphasis on studies tha...

Xu-Yang Huang, Xin-Yue Zhang, Qi Zhu · 0 citations
Review Open access Oct 2026

Reprogramming the gut–brain axis in neurodegeneration: comparative microbiome, metabolite, immunometabolic, polyphenol, probiotic, and epigenetic mechanisms in Alzheimer’s and Parkinson’s diseases

The gut–brain axis has emerged as a central mechanistic framework linking dietary bioactives, microbial ecology, and neurodegenerative disease progression. Similar microbiome-related mechanisms have also been implicated in colorectal cancer, suggesting potential shared links between microbial dysbiosis, inflammation, a...

Yu-Jie Cheng, Mei-Ping Tao, Ke-Xin Qian et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.